GlassScriptPhysician profile
Mamta Verma
NPI 1275749335
$18,192.50
in general payments reported to CMS, 2019-2025
21 companies · $283 in 2025
The $283 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $3,396 · 2021: $258 · 2022: $175 · 2023: $275 · 2024: $321 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.54 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $12,283.79 | 2019-2020 | |
| Genentech USA, INC. | $4,347.82 | 2019-2024 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Emd Serono, INC. | $207.35 | 2019-2024 | Mavenclad |
| Biogen, INC. | $202.79 | 2019-2023 | Tysabri |
| Argenx US, INC. | $191.33 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $145.98 | 2021-2025 | Dysport |
| Abbvie INC. | $143.83 | 2021-2025 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $109.76 | 2021-2022 | |
| Tg Therapeutics, INC. | $106.83 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $97.47 | 2021 | |
| Novartis Pharmaceuticals Corporation | $89.62 | 2019-2023 | |
| Lilly USA, LLC | $60.78 | 2019 | |
| Genentech, INC. | $49.95 | 2021 | |
| Celgene Corporation | $41.02 | 2022-2025 | Zeposia |
| Ucb, INC. | $21.60 | 2024 | Rystiggo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.70 | 2023 | |
| Allergan, INC. | $17.77 | 2019 | |
| Vanda Pharmaceuticals INC. | $15.73 | 2025 | Ponvory |
| Lundbeck LLC | $15.01 | 2020 | |
| Neurelis, INC. | $13.40 | 2024 | Valtoco |
| Acorda Therapeutics, INC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mamta Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.